Companies Form Expert Working Group to Introduce Essential Tools for AAV Development and Research ProfessionalsSAN FRANCISCO / ACCESSWIRE / June 27, 2024 / Form Bio, the provider of advanced computational life sciences technology and PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a range of new initiatives aimed at advancing and unifying the AAV industry. The initiatives, including an AAV data dictionary, open-source tools and more, are being driven by a new AAV Working Group, jointly assembled by Form Bio and PacBio and composed of leading AAV experts across industry and academia. The resulting materials are being made available on a new AAV Resource Hub at aav.formbio.com.AAV is widely recognized as one of the most promising technologies for gene therapy due to its non-pathogenic nature. However, collaboration on AAV-based programs is often hindered by industry silos that lead to divergent terminology and methods, which can differ widely between various companies and institutions operating at the forefront of AAV innovation. In addition, the lack of standard definitions and practices works against uniformity of regulatory submissions, making it harder and more time consuming for regulatory agencies to evaluate potential new therapies.In response, Form Bio and PacBio have convened leading experts to form an AAV Working Group dedicated to developing and promoting standardized nomenclature and reporting practices to foster consistency and reliability in AAV research and development. The charter of the newly formed AAV Working Group is to develop standardized nomenclature, establish standardized reporting, and promote widespread adoption of these initiatives.Members of the AAV Working Group include:Nam Tonthat, Ph.D - Asklepios BioPharmaceuticalPranam Chatterjee, Ph.D - Department of Biomedical Engineering, Duke UniversityDouglas McCarty, Ph.D - Nationwide Children's HospitalPhillip W.L

Presentations Focused on How AI is Leveraged to Optimize Gene Therapy Construct Designs for Safety, Yield and Efficacy - Resulting in Faster Delivery to Market With a Higher Probability of SuccessSAN FRANCISCO, CA / ACCESSWIRE / May 3, 2024 / Form Bio, the breakthrough computational life sciences solutions provider, today announced that it will deliver multiple presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place May 7-11, 2024, in Baltimore, Maryland. The presentations include an oral presentation, ASGCT workshop, sponsored symposium, and "Meet the Expert" sessions at the company's booth.Oral PresentationTitle: Analyzing and Improving AAV Vector Design with Long Read Sequencing and AnalysisPresenter: Amicia Elliott, Ph.D., Product Director, Life Sciences, Form BioSession Title: AAV Vector Biology and Development IIIDate and Time: Saturday, May 11, 2024, 10:15-10:30 a.m. ETAbstract Number: 387Room: Ballroom 4Session PresentationsASGCT WorkshopTitle: AAV Manufacturing for CMC Success: Translating Preclinical Gene Therapy Products to Clinical SuccessPresenter: Claire Aldridge, Ph.D., Chief Scientific Officer, Form BioDate and Time: Tuesday, May 7, 2024, 11-11:45 a.m. ETLocation: Ballroom 3Sponsored SymposiumTitle: You Have a Great Technology...Now What?Presenter: Amicia Elliott, Ph.D., Product Director, Life Sciences, Form BioDate and Time: Friday, May 10, 2024, 1:30-3:15 p.m. ETLocation: Room 339-342Form Bio Booth SessionsMeet the ExpertTitle: Sandwiches With Solid BiosciencesPresenter: Adam Cockrell, Ph.D., Senior Director of Vector Biology, Solid BiosciencesDate and Time: Tuesday, May 7, 2024, 6-6:30 p.m. ETBooth Number: 729Meet the ExpertTitle: Cookies and CharacterizationPresenter: Nadia Sellami, Ph.D., Senior Specialist, PacBioDate and Time: Wednesday, May 8, 2024, 3:15-3:45 p.m

Bringing Together the Top Minds Across Vector Engineering, Viral Vector Delivery Systems and Next-Generation Gene Transfer Technologies Further Cements Form Bio's Position as a Leader in AI-Driven Cell and Gene TherapyDALLAS, TX / ACCESSWIRE / April 18, 2024 / Form Bio, the breakthrough computational life sciences solutions provider, today announced the creation of a new Scientific Advisory Board (SAB). This esteemed board will provide strategic guidance and consultation on the company's research and development efforts, particularly in the life sciences sector, serving biotech and pharma customers.The SAB, comprised of renowned experts from industry and academia, brings deep knowledge and a shared commitment to advancing science for improved therapeutic development, clinical outcomes and human health. Tasked with providing strategic counsel and critical expertise, the collective experience of Form Bio's SAB aligns with the company's mission to advance cell and gene therapies for the AI era."The formation of our distinguished SAB reaffirms our commitment to advancing innovative cell and gene therapy development. Our focus is on leveraging AI-based technology to accelerate and optimize construct designs for safety, yield and efficacy, ensuring cell and gene therapies reach the market faster and with a higher probability of success," said Kent Wakeford, Form Bio's co-founder and co-chief executive officer. "We look forward to leveraging the collective expertise of our SAB as we advance our in silico programs from AAV-based gene therapy to other modalities to make a meaningful impact on patients affected by debilitating diseases."New Members of Form Bio's SAB include:Steven Gray, Ph.D. , is a professor in the Department of Pediatrics at the University of Texas Southwestern